EMBRYO-FETAL TOXICITY
See full prescribing information for complete boxed warning
- Trade Name: Daurismo (Pfizer)
- Indications: indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
- Class: Hedgehog (Hh) signaling pathway inhibitor
- Half-life: 17.4 hours
- FDA Approval Date: 11/21/2018
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: can cause fetal harm, not recommended for use during pregnancy
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
